Smith & Nephew plc - SNN STOCK NEWS

Smith+Nephew (NYSE:SNN) has launched the UltraTRAC QUAD ACL Reconstruction Technique, featuring the QUADTRAC Quadriceps Tendon Harvest Guide System and ULTRABUTTON Adjustable Fixation Devices. These innovations aim to enhance procedural efficiency in ACL surgeries, which are projected to exceed 350,000 cases in the U.S. by 2023 with a 5.7% annual growth rate. The QUADTRAC System offers improved tendon visualization and controlled harvesting techniques, facilitating better surgical outcomes. This initiative reinforces Smith+Nephew's commitment to addressing surgeon preferences and expands its offerings within the sports medicine sector.

Smith+Nephew (NYSE: SNN) has released a systematic literature review and meta-analysis highlighting its VISIONAIRE Patient-Specific Instrumentation (PSI), which has shown enhanced alignment accuracy and efficiency in Total Knee Arthroplasty (TKA). The analysis included 25 studies, indicating significant improvements such as a 40% reduction in outlier odds for mechanical axis alignment, decreased operating room time, and an 11.1% reduction in hospital stay length. The findings, published in the Archives of Orthopaedic and Trauma Surgery, demonstrate that VISIONAIRE PSI leads to better patient outcomes and lower total hospital costs compared to conventional TKA methods.

Smith+Nephew (NYSE:SNN) announced that its LEAF Patient Monitoring System received an Innovative Technology designation from Vizient, the largest healthcare performance improvement company in the U.S. The award highlights products that enhance clinical care and safety. The LEAF System, the first wearable solution meeting NPIAP guidelines, has shown to improve adherence to patient turning protocols by 98% and reduce hospital-acquired pressure injuries by 73%. Its implementation resulted in estimated annual cost savings of up to $1.8 million in a critical care unit. Pressure injuries represent a rising hospital-acquired complication, costing roughly $11 billion in preventable treatments annually.

On November 1, 2022, Smith+Nephew (NYSE:SNN) introduced the JOURNEY II ROX Total Knee Solution, designed for total knee arthroplasty. This innovative solution combines advanced bearing materials with cementless tibia fixation, enhancing surgical efficiency. It integrates technologies like CONCELOC Advanced Porous Titanium and OXINIUM Oxidized Zirconium for maximum performance. Compatible with the CORI Surgical System, it supports robotics-assisted procedures. Smith+Nephew will showcase this product at the AAHKS Annual Meeting, highlighting its commitment to advancing knee surgery technology.

Smith+Nephew (LSE:SN, NYSE:SNN) announces the successful first cases of revision knee replacement using its CORI Surgical System on August 17, 2022. The company is the first in orthopaedics to obtain FDA 510(k) clearance for a robotic-assisted platform for revision indications. This innovation allows surgeons to create patient-specific 3D models and improve precision in surgery. The CORI system now supports total, partial, and revision knee arthroplasties, enhancing surgical efficiency and patient care.

Smith+Nephew (NYSE:SNN) announced on Sept. 21, 2022, an expansion of its medical education curriculum via advanced simulation technologies, including virtual reality and augmented reality. Healthcare professionals can now access training in orthopaedics, robotics, and sports medicine globally. A survey revealed that 90% of participants support the use of virtual reality in future training. Smith+Nephew aims to enhance surgical education and patient outcomes by integrating cutting-edge technology into its Academy program, with new educational modules launching soon.

Smith+Nephew (NYSE: SNN) announced significant findings from a randomized controlled trial for its REGENETEN Bioinductive Implant in rotator cuff repair. The interim results showed an 86% reduction in re-tear rates, with a rate of 3.5% in patients receiving the implant compared to 25% for traditional repair alone. The study was presented at the SECEC-ESSE Congress in Dublin. These results may enhance recovery for approximately 545,000 annual procedures globally, highlighting the implant's potential impact on patient outcomes and market positioning.

Smith+Nephew (NYSE: SNN) announces the OXINIUM Technology Tour of Change will be featured at the Pro Football Hall of Fame from August 4-6, 2022, to educate retired players and the community on joint replacement technology. The company partners with Hall of Fame Health to provide access to OXINIUM products. OXINIUM Technology has been recognized for its superior performance in hip and knee replacements over 20 years, showing low revision rates. Testimonials from Hall of Famers emphasize the technology's positive impact on their lives.

Smith+Nephew (LSE: SN, NYSE: SNN) is showcasing advanced joint repair solutions at the AOSSM Annual Meeting in Colorado from July 13-17, 2022. Key highlights include the REGENETEN Bioinductive Implant, aimed at treating 17 million individuals with rotator cuff diseases in the U.S., which has shown potential to expedite healing and reduce re-tears. Other innovations include the Reimagine Reconstruction portfolio for knee injuries and the CAP-FIX Suture Passer for hip repairs. The event will also feature live surgery demos and educational opportunities for surgeons.